Fund of the week: Janus Henderson (Healthcare)

Janus Henderson's Healthcare Team is the life-sciences franchise of Janus Henderson Group, a global active asset manager that ran approximately $480 billion at 31 March 2026. It runs the Global Life Sciences strategy (from 1998), a biotechnology franchise built out from 2018, and a biotech long/short strategy launched in 2020, from a Denver-based team led by Andy Acker.

Two things place it in this publication's field of view. The biotech long/short strategy allocates up to 30 percent of capital to pre-IPO private and crossover rounds, per Institutional Investor, and several of its largest public holdings are royalty payors under Halozyme's ENHANZE platform. On 30 June 2026 Janus Henderson was taken private and delisted from the NYSE. The funds hold no purchased royalties and no product IP.

At a glance

• What it is: the healthcare and life-sciences investment franchise of Janus Henderson Group, running long-only and long/short public-equity strategies with a private-crossover sleeve
• Parent: Janus Henderson Group Ltd (formerly Janus Henderson Group plc), London (201 Bishopsgate), CEO Ali Dibadj; heritage to 1934, Janus and Henderson merged May 2017
• Ownership: private since 30 June 2026, held by Trian Fund Management, General Catalyst, and the Qatar Investment Authority after a $52.00 per share cash take-private; delisted from the NYSE. Trian had held roughly 20 percent since 2020
• Parent AUM: approximately $480 billion at 31 March 2026, from approximately $493 billion at 31 December 2025
• Healthcare team: Denver-based, roughly nine professionals, led by Andy Acker (PM since 2007 on Global Life Sciences, since 2018 on biotech; joined 1999) and Daniel Lyons (co-PM since 2023)
• Vehicles: Global Life Sciences (US mutual fund plus a Luxembourg SICAV); Horizon Biotechnology Fund (SICAV, launched December 2018, NASDAQ Biotechnology TR benchmark); a biotech long/short strategy (from 2020, up to 30 percent private/crossover, closed to new investors in late 2024)
• US Global Life Sciences Fund: approximately $5.4 billion total net assets; top ten holdings roughly 39 percent of assets
• Royalty interests: none held directly; several holdings are royalty payors. Owned IP: none identified
• Recognition: biotech team won the With Intelligence HFM US Sector Specialist award for 2023

Fund-level figures below are share-class or vehicle snapshots, dated as noted.

A note on scope

The Healthcare Team is an investment franchise within a larger asset manager, not a standalone fund. It is distinct from the parent, Janus Henderson Group, which as of 30 June 2026 is privately held. The healthcare vehicles are open-ended pooled funds (a US mutual fund, Luxembourg SICAVs, and a UCITS) plus a separately managed biotech long/short strategy.

Investment thesis and mandate

The stated approach is fundamental, science-led investing in companies addressing high unmet medical need or improving healthcare efficiency, across pharma, biotech, medtech, diagnostics, tools, and services. The team uses a proprietary value-at-risk framework and holds small, less liquid names alongside mega-cap pharma. Instrument choice is set by vehicle: long-only equity in the mutual fund and UCITS, long/short plus private in the biotech vehicle. There is no royalty, credit, or revenue-interest mandate.

In the mid-year checkup (data to 30 June 2026), Acker and Lyons attributed healthcare's 2026 underperformance to sentiment, citing the Iran conflict and AI-led market leadership, and pointed to continued biopharma innovation, improving managed-care visibility, and lower medtech and tools valuations.

How capital enters and returns

Three vehicle families sit at different points on the risk and liquidity spectrum.

The three vehicle families: long-only Global Life Sciences, the Horizon Biotechnology UCITS, and the biotech long/short strategy with its private-crossover sleeve.

Global Life Sciences (long-only, global). Inception 31 December 1998, Acker lead PM since May 2007, Lyons co-PM since 2023. Offered as a US mutual fund and a Luxembourg SICAV. Large-cap tilted, global, with a small/mid-cap sleeve.

US-fund performance (JFNIX institutional shares) was approximately 18.8 percent over one year, 11.7 percent annualised over three years, and 8.0 percent annualised over five years in early 2026, with a 0.78 percent ongoing charge.

Horizon Biotechnology Fund (long-only biotech). Luxembourg SICAV launched 10 December 2018 (ISIN LU1897414303), benchmarked to the NASDAQ Biotechnology TR Index with a 2 percent annual outperformance target over rolling five-year periods, before charges. At least 80 percent in biotech equities of any size, any country.

Biotech long/short (from 2020). Long and short biotech positions, plus up to 30 percent of capital in pre-IPO private and crossover investments. Closed to new investors in late 2024.

Financial profile and assets

Fig. 2 — Parent-level AUM, June 2024 to March 2026, last publicly reported before the take-private and NYSE delisting.

The public book

Top ten Global Life Sciences holdings were roughly 39 percent of assets: Eli Lilly (near 9.5 percent), Johnson & Johnson, AstraZeneca, UnitedHealth, AbbVie, Abbott, argenx, Boston Scientific, Sanofi, and Novartis. The biotech vehicles skew smaller and more clinical.

The take-private

Under a definitive agreement dated 21 December 2025, Trian (Nelson Peltz), General Catalyst (Hemant Taneja), and the Qatar Investment Authority took the company private at $52.00 per share in cash. Shareholders approved in April 2026, regulatory approvals and client consents were secured by 18 June 2026, and the deal completed on 30 June 2026 with an NYSE delisting.

The entity is now Janus Henderson Group Ltd, Ali Dibadj continuing as CEO. As a private company it no longer files quarterly AUM and flow releases; the regulated funds still publish factsheets and holdings.

Investors and distribution

The healthcare vehicles are open-ended funds offered to retail and institutional investors. The US Global Life Sciences Fund is a Janus Investment Fund series; the Global Life Sciences Equities Fund and Horizon Biotechnology Fund are Luxembourg SICAVs, with First Independent Fund Services as Swiss representative and Banque Cantonale de Genève as Swiss paying agent.

The biotech long/short strategy is offered to qualified investors and closed to new investors in late 2024. No limited-partner roster applies; holders are fund shareholders.

Governance and compensation

The team is Denver-based, led by Andy Acker, CFA (Global Life Sciences PM since 2007, biotech since 2018, head of the Health Care Sector Research Team; joined 1999; Harvard BS and MBA). Daniel Lyons, PhD, CFA, co-PMs Global Life Sciences (since 2023) and biotech.

Agustin Mohedas, PhD, is a biotech PM (previously RA Capital Management and Eventide; joined 2019; Texas A&M, Harvard-MIT PhD). Vish Sridharan, MD, covers biotech; Luyi Guo, PhD, CFA, pharmaceuticals; Tim McCarty, CFA, Adam Poussard, CFA, and Lauren Petite, medical technology. The firm describes roughly nine professionals with more than a hundred years of combined experience.

Above the funds sits Janus Henderson Group Ltd, owned by Trian, General Catalyst, and the QIA since 30 June 2026, with Ali Dibadj as CEO. The regulated fund vehicles retain their own boards and depositaries. No compensation disclosure exists for the healthcare team.

IP, royalties, and the economics of return

No owned patent estate and no purchased royalty are attributable to the funds. Return comes from equity appreciation, dividends in the large-cap book, and, in the biotech long/short strategy, long and short selection and mark-ups on private and crossover positions when portfolio companies raise, IPO, or are acquired.

Royalty exposure among holdings

Several top-ten holdings carry royalty obligations under Halozyme's ENHANZE subcutaneous-delivery platform, a royalty-model business whose licensees include Roche, Takeda, Pfizer, Johnson & Johnson, AbbVie, Eli Lilly, and Bristol Myers Squibb. argenx pays Halozyme a tiered mid-single-digit royalty on ENHANZE co-formulated products (VYVGART Hytrulo/SC), plus per-target and milestone payments.

Eli Lilly, Johnson & Johnson, and AbbVie are ENHANZE licensees and royalty payors on relevant products. The remaining large-cap holdings pay and receive royalties in the normal course of licensing. In each case the position is common equity; the royalty streams accrue to the licensor, not to the fund.

Private and crossover investing

The biotech long/short strategy allocates up to 30 percent of capital to pre-IPO private and crossover rounds. The Global Life Sciences and biotech funds participate in public follow-ons and PIPEs.

Equity and research

The Health Care Sector Research Team publishes sector outlooks and conference notes, including the 2026 outlook and JPM conference takeaways. No purchased royalty, revenue interest, structured-credit facility, or synthetic royalty is held by the funds.

Holdings, as of January 2026

Top ten Global Life Sciences holdings, roughly 39 percent of assets. Weights not shown.

Blue team and red team

Blue team

• Global Life Sciences strategy dates to 1998, same lead PM since 2007
• A funded private-crossover sleeve, up to 30 percent of the biotech long/short strategy, in pre-IPO rounds
• Several top-ten holdings (argenx, Eli Lilly, Johnson & Johnson, AbbVie) are ENHANZE royalty payors, linking the equity book to royalty economics
• Deep scientific staffing (MDs, PhDs) and a drug-development risk overlay; 2023 HFM sector-specialist award
• Parent scale (approximately $480 billion) and widely distributed sector research

Red team

• No purchased royalty, revenue interest, or structured credit held by the funds; royalty exposure is indirect, through equity in royalty payors, not ownership of streams
• Core healthcare book is large-cap, long-only public equity
• Parent now private; quarterly AUM and flow visibility ends, though the funds still publish
• Fund-level sizing is partly dated (Horizon Biotechnology Fund figure is February 2024)
• The most royalty-relevant sleeve, the biotech private book, is the least disclosed: size, positions, and terms are not public
• Key-person concentration around Acker

Implications for the pharmaceutical royalty and biotech capital markets

Janus Henderson intersects royalty markets in three ways, none as a royalty buyer. Its biotech private-crossover sleeve participates in the same late-stage private and crossover rounds royalty and structured-credit providers evaluate.

Its funds anchor public follow-ons and PIPEs, including the marketed equity that can accompany non-dilutive financings. And its holdings include ENHANZE royalty payors, so the equity book carries indirect exposure to a royalty-model platform. Royalties are not an instrument in the franchise.

Recent developments, as of August 2026

• Take-private completed 30 June 2026 at $52.00 per share (Trian, General Catalyst, QIA); NYSE delisting; entity now Janus Henderson Group Ltd, Dibadj continuing as CEO
• Shareholder approval April 2026; regulatory approvals and client consents secured 18 June 2026
• Q1 2026 parent AUM approximately $480 billion, net inflows of approximately $2.9 billion
• Biotech long/short strategy remained closed to new investors
• No royalty or revenue-interest activity identified

Financial history and recent developments

Conclusion

Janus Henderson's healthcare franchise runs long-only and long/short public-equity strategies with a private-crossover sleeve, inside a $480 billion parent that went private on 30 June 2026. It holds no royalty streams. Its royalty relevance is indirect: a biotech private-crossover sleeve, participation in equity financings, and equity in ENHANZE royalty payors including argenx, Eli Lilly, Johnson & Johnson, and AbbVie.

All information in this article was accurate as of the research date and is derived from publicly available sources including company press releases, SEC filings, fund factsheets and prospectuses, data-vendor records, and financial news reporting. Janus Henderson Group Ltd is, as of 30 June 2026, a privately held company and no longer files quarterly public results; parent AUM figures cited are the last publicly reported. Fund-level figures are share-class or vehicle snapshots, may be dated, and are not strategy-level committed capital. Holdings and royalty relationships described are as of the cited dates and do not constitute a recommendation. The funds hold no pharmaceutical royalties or product IP identified in this research. Information may have changed since publication. This content is for informational purposes only and does not constitute investment, legal, or financial advice. The author is not a lawyer or financial adviser.